After a therapeutic dose, APAP is mostly converted to pharmacologically inactive glucuronide (APAP-gluc, 5257% of urinary metabolites) and sulfate (APAP sulfate, 3044%) conjugates, with a minor fraction being oxidized to a reactive metabolite NAPQI (510%) (Figure 1)
Clinical treatment
Yes, IGF-1 LR3 can lead to abnormal bone or tissue growth if used excessively
Additional information DISCLOSURE/CONFLICT OF INTEREST Michael Berk declares that over the past three years, he has received compensation from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Norvatis, Mayne Pharma and Servier